FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Dynavax pockets $30M to fund new development

Dynavax Technologies has gained $30 million in new financing to help accelerate the development of its allergy products. Deerfield Management is providing the money, which will go to finance a late-stage ragweed trial and preclinical programs for peanut and cat allergies. The Phase III study of Tolamba will enroll about 300 volunteers. In the financing deal, Dynavax will not have to repay up to $9 million for the study if it proves unsuccessful.

- check out the release
- here's the AP report for more information

Related Articles:
Dynavax stock jumps on hep B data. Report
Dynavax, AstraZeneca ink $136M deal. Report
Dynavax Hep B vaccine successful in Phase II. Report

More stories about Phase III   AstraZeneca   Phase II   preclinical   Dynavax Technologies  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 39 + 45?
To combat spam, please solve the math question above.